Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
|Slideshows|February 7, 2020
Cystic Fibrosis and Personalized Medicine: A Brief History
Author(s)Leo Robert
These concise summaries outline key developments in the evolution of a promising genetics-based approach to cystic fibrosis treatment.
Advertisement
Personalized medicine, also known as precision medicine, continues to advance as a genetics-based approach to treating patients with cystic fibrosis (CF). In this approach, personalized interventions are applied for patients who have specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Scroll through the slides below to find concise summaries of key developments in the evolution of personalized, or precision, medicine for patients with CF.
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
5